However, despite its anti-inflammatory and cardioprotective properties in cellular and animal models, a number of prospective human studies have indicated a positive, rather than the expected negative, association between circulating adiponectin levels and all-cause and cardiovascular mortality across many clinical conditions including diabetes, CVDs, and chronic kidney disease [19, 20]. Here, ADIPOQ is linked to diabetes mellitus.